Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with a few insights on Pharmacyclics, Inc. (NASDAQ:PCYC), following the release of the company’s fourth-quarter results, posting GAAP net …
In a research report published Tuesday, BTIG analyst Hartaj Singh maintained a Buy rating on Pharmacyclics (NASDAQ :PCYC) with a $225 price target, …
Pharmacyclics, Inc. (NASDAQ:PCYC) today provided its preliminary unaudited 2014 U.
In a research report released Monday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a price target of …
In a research report sent to investors today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a price …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a $188 price target, following the company third-quarter results, posting diluted GAAP EPS …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a price target of …
In a research report issued Monday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Pharmacyclics (NASDAQ:PCYC) and slightly raised his price target …
In a research report issued yesterday, William Blair analyst Y Katherine Xu maintained an Outperform rating on Pharmacyclics (NASDAQ:PCYC) with a price target of …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a price target of $183, after …
